Three Or More Ring Hetero Atoms In The Pentacyclo Ring System Patents (Class 546/48)
-
Patent number: 6228855Abstract: Aromatic camptothecin ester compounds having the formula: are described as well as formulations containing the compounds. Methods of treating cancer and/or tumors are also disclosed.Type: GrantFiled: August 3, 1999Date of Patent: May 8, 2001Assignee: The Stehlin Foundation for Cancer ResearchInventors: Zhisong Cao, Beppino C. Giovanella
-
Patent number: 6218540Abstract: A process for preparing the anti-cancer drug camptothecin (CPT) and certain derivatives thereof. The process includes the reacting of three base reagents and a five-step process for synthesizing optically pure CPT in high overall yield from inexpensive starting materials.Type: GrantFiled: May 4, 1999Date of Patent: April 17, 2001Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Marco Ciufolini, Frank Roschangar
-
Patent number: 6214836Abstract: Novel water soluble C-ring analogues of 20(S)-camptothecin having the general formula 1. All the compounds of the formula 1 are prepared from the compounds of the general formula 2 having 20(S)-chiral carbon. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties. The invention also provides an alternate process for the preparation of known C-5 substituted compounds of the formula 1.Type: GrantFiled: December 19, 1996Date of Patent: April 10, 2001Assignees: Dr. Reddy's Research Foundation, Reddy Cheminor, Inc.Inventors: Subrahmanyam Duvvuri, Venkateswarlu Akella, Sharma Manohara Vedula, Rao Venkateswara Kalla, Srinivas S.S.V. Akella
-
Patent number: 6211371Abstract: A method of synthesizing compounds having the formula via a 4+1 radical annulation/cyclization wherein the precursor is reacted with an aryl isonitrile having the formula wherein X is selected from the group consisting of Br and I, ≡Y is ≡N or ≡C—R3, R1, R2, and R6 are independently hydrogen, a normal alkyl group, a branched alkyl group, an allyl group, a benzyl group, an alkynyl group, a propargyl group, an alkoxyl group, a halogen group, a trialkylsilyl group, an amino group, an alkyl amino group, a dialkylamino group, an aminoalkyl group, a cyano group, or R16CO—, wherein R16 is an alkyl group, an alkoxyl group, or an amino group, R3 is hydrogen, a normal alkyl group, a branched alkyl group, an allyl group, a benzyl group, an alkynyl group, a propargyl group, an alkoxyl group, a halogen group, a trialkylsilyl group, an amino group, an alkyl amino group, a dialkylamino group, an aminoalkyl group, a cyano group, or R16COType: GrantFiled: January 15, 1998Date of Patent: April 3, 2001Assignee: University of PittsburghInventors: Dennis P. Curran, Hubert Josien, Sung Bo Ko
-
Patent number: 6211192Abstract: The present invention relates to alkynyl-substituted camptothecins of formula (I) wherein X, R1, R2 are as defined herein, and the pharmaceutically salts thereof. These compounds are useful in therapy as antitumor agents.Type: GrantFiled: August 12, 1999Date of Patent: April 3, 2001Assignee: Pharmacia & Upjohn S.p.A.Inventors: Ilaria Candiani, Angelo Bedeschi, Giuseppina Visentin, Maria Chiara Fagnola, Laura Capolongo
-
Patent number: 6207832Abstract: A compound has the formula in racemic form, enantiomerically enriched form or enantiomerically pure form. R6 is preferably —Si(R8R9R10) or —(R7)Si(R8R9R10), wherein R7 is an alkylene group, an alkenylene group, or an alkynylene group; and R8, R9 and R10 are independently a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, an aryl group or a —(CH2)NR11 group, wherein N is an integer within the range of 1 through 10 and R11 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group, —SRc or a nitro group. R1-R can be broadly substituted. R5 is preferably a C1-10 alkyl group, an alkenyl group, an alkynyl group, or a benzyl group. R13 is preferably H, F or —CH3. R16 is R16 is —C(O)Rf or H. The E-ring (the lactone ring) may be opened. A method of synthesis of compound (1) and intermediates in the synthesis thereof are provided.Type: GrantFiled: April 9, 1999Date of Patent: March 27, 2001Assignee: University of PittsburghInventors: Dennis P. Curran, Bom David, Thomas G. Burke
-
Patent number: 6207673Abstract: The present invention provides covalent conjugates of topoisomerase I and topoisomerase II inhibitors. Such compounds have a structure according to formula I: TI—L—TII (I) wherein: TI is a topoisomerase I inhibitor such as a camptothecin group; TII is a topoisomerase II inhibitor such as an amsacrine, ellipticine, epipodophyllotoxin, or anthracycline antibiotic group; and L is a linking group. The compounds are useful for inhibiting topoisomerase I and II enzymes, for promoting cellular differentiation, and for treating cancer.Type: GrantFiled: March 12, 1997Date of Patent: March 27, 2001Assignees: The University of North Carolina at Chapel Hill, Yale UniversityInventors: Kuo-Hsiung Lee, Yung-Chi Cheng, Xin Guo, Kenneth F. Bastow, Hui-Kang Wang
-
Patent number: 6194580Abstract: The present invention is directed to methods of forming esters of tertiary alcohols. The methods include reacting a compound containing a tertiary alcohol with an acyl heteroaromatic ion-based compound of the formula: wherein R1 is an aromatic or aliphatic acid residue; Y is O or S; Z is CR2 or N; X is selected from the group consisting of wherein R2 and R3 are independently selected from the group consisting of H, C1-6 alkyls, C1-6 substituted alkyls, C1-6 heteroalkyls, C3-8 branched alkyls, C3-8 cycloalkyls, C1-6 substituted heteroalkyls, aryls, substituted aryls, C1-6 alkyl aralkyls, C1-6 heteroalkyl aralkyls, C3-8 branched alkyl aralkyls and C3-8 cycloalkyl aralkyls; and R2′ is the same as R2 except that R2′ is not H; in the presence of a lanthanideIII metal-based catalyst and a base.Type: GrantFiled: February 4, 2000Date of Patent: February 27, 2001Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Annapurna Pendri, Hong Zhao
-
Patent number: 6194579Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: December 23, 1999Date of Patent: February 27, 2001Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 6184379Abstract: The invention concerns rhodamine derivatives of the general formulae in which Ca-Cd each denote a C atom, and Ca and Cb as well as Cc and Cd are either linked together by a single bond or by a double bond; X1 to X16 denote independently of one another halogen, sulfonic acid, hydrogen or an alkyl residue with 1-20 C atoms in which the alkyl residue can be substituted with one or several halogen or sulfonic acid residues; R1 and R2 are either identical or different and denote either hydrogen, alkyl with 1-20 C atoms, polyoxyhydrocarbyl units, phenyl or phenylalkyl with 1-3 carbon atoms in the alkyl chain in which the alkyl and/or phenyl residues can be substituted by one or several hydroxy, halogen, sulfonic acid, amino, carboxy or alkoxycarbonyl groups where alkoxy can have 1-4 carbon atoms, R1 contains at least one activatable group, R2 and X4 can be optionally linked together via a bridge composed of 0-2 C atoms.Type: GrantFiled: June 2, 1999Date of Patent: February 6, 2001Assignee: Roche Diagnostics GmbHInventors: Hans-Peter Josel, Rupert Herrmann, Dieter Heindl, Klaus Muhlegger, Gregor Sagner, Karl Heinz Drexhage, Jorg Frantzeskos, Jutta Arden-Jacob
-
Patent number: 6184228Abstract: The present invention is directed to a method for selecting compounds for use in treating sickle cell disease in a patient. The method comprises the steps of selecting a first set of HbS ligands from a first group of chemical compounds, selecting from the first set of HbS ligands a seconds set that exhibit inhibition of HbS polymerization, and selecting from the second set a third set that display anti-sickling activity of red blood cells when in the presence thereof. The method may include the step of performing a methemoglobin S proteolysis assay measuring a percent protease protection for each compound. The method may additionally include the steps of measuring HbS aggregation, inhibition of protease, deoxy-HbS gelation inhibition activity, O2 affinity of HbS, and cytotoxic effect to cell activity. The method may further include assessing red blood cell morphology, and eliminating compounds that contain moieties that bind to heme.Type: GrantFiled: May 25, 1999Date of Patent: February 6, 2001Assignee: ANADYS Pharmaceuticals, Inc.Inventors: Alan F. Corin, Andrew A. Pakula, Julianne Bryan
-
Patent number: 6177568Abstract: Intermediates for the synthesis of camptothecin of the formula II wherein: R1 is —(CH2)2NR1R2, where R1 is an amino protecting group and R2 is C2-C5 alkyl, hydroxyethyl or acetoxyethyl group, and of the formula III wherein: n is 1 or 2; R3 is hydrogen or —OR4, where R4 is hydrogen, —COR5, —CONHR6 or CH2OR7, where R5 is methyl or —CH2OCH3, R6 is isopropyl, phenyl or —CH2CH2Cl, and R7 is methyl, ethyl or —CH2CH2OCH3; with the proviso that when n is 2, R3 is not hydrogen.Type: GrantFiled: March 26, 1999Date of Patent: January 23, 2001Assignee: Chong Kun Dang Corp.Inventors: Sang Sup Jew, Hee Soon Lee, Joon Kyum Kim, Kwang Dae Ok, Kyeong Hoi Cha, Myoung Goo Kim, Kwang Kyun Lee, Jong Min Kim, Hee Jin Kim, Jeong Mi Hah
-
Patent number: 6177439Abstract: Novel water soluble C-ring analogues of 20(S)-camptothecin having the general formula 1, All the compounds of the formula 1 are prepared from the compounds of the general formula 2 having 20(S)-chiral carbon where R1 to R5 have the meaning given above. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties.Type: GrantFiled: December 19, 1996Date of Patent: January 23, 2001Assignees: Reddy's Research Foundation, Reddy-Cheminor, Inc.Inventors: Subrahmanyam Duvvuri, Venkateswarlu Akella, Sharma Manohara Vedula, Sastry V. R. S. Thungathurthi, Vamsee Krishna Chintakunta, Shobha Madabhushi
-
Patent number: 6169080Abstract: This invention relates to novel derivatives of camptothecin, and will, particularly to derivatives having a substitution at the C-7 position, or at one of the C-9, C-10, C-11 or C-12 positions, or to disubstituted derivatives having a first substitution at C-7 and a second at one of C-9, C-10, C-11 or C-12. The invention also includes methods of using the compounds as Topoisomerase I inhibitors to treat patients with cancer. The invention also includes pharmaceutical formulations which consist of the novel compounds in solution or suspension with one or more pharmaceutical excipients or dilutes.Type: GrantFiled: February 11, 1998Date of Patent: January 2, 2001Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Kochat Haridas, P. Seetharamulu, Dasharatha G. Reddy, Shijie Yao, Pavankumar N.V. Petluru, Dhanabalan Murali
-
Patent number: 6156754Abstract: The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the A or B ring of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.Type: GrantFiled: March 24, 1999Date of Patent: December 5, 2000Assignee: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Karsten von dem Bruch, Jorg Baumgarten, Michael Sperzel
-
Patent number: 6156897Abstract: Methods for purifying 20(S)-camptothecin are described. The 20(S)-camptothecin in purified form is useful in the treatment of cancer.Type: GrantFiled: August 16, 1999Date of Patent: December 5, 2000Assignee: The Stehlin Foundation for Cancer ResearchInventor: Hellmuth R. Hinz
-
Patent number: 6156236Abstract: A conductive organopolysiloxane composition is provided which includes (A) 100 parts by weight of an organopolysiloxane; and (B) 0.1 to 800 parts by weight of a conductive material obtained by subjecting a member selected from the group consisting of a conductive metal, a conductive metal compound, a filler surface-treated with a conductive metal and a filler surface-treated with a conductive metal compound, to surface treatment with a compound selected from the group consisting of a compound represented by the formula (1) and a compound represented by the formula (2). ##STR1## wherein R.sup.1 represents --O-- or --NH--, and R.sup.2 represents a hydrogen atom or a phenyl group. This composition is useful for the formation of a silicone rubber having a sufficient electrical conductivity and also stably retainable of electrical conductivity almost without undergoing a change in electrical conductivity even in a high-temperature environment.Type: GrantFiled: March 19, 1999Date of Patent: December 5, 2000Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Osamu Hayashida, Takeo Yoshida, Toshihide Shimizu, Tamaki Iida
-
Patent number: 6143891Abstract: The present invention relates to a process for preparing camptothecin and camptothecin analogs of Formula (I) from compounds of Formula (II) and to novel intermediates useful in their preparation, ##STR1## wherein R.sub.1 to R.sub.6 represent various substituents.Type: GrantFiled: May 14, 1998Date of Patent: November 7, 2000Assignee: Glaxo Wellcome Inc.Inventors: Francis Gerard Fang, Shiping Xie
-
Patent number: 6140328Abstract: The invention provides compounds of formula I: whereinR.sub.1 -R.sub.8 and X and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.Type: GrantFiled: December 12, 1997Date of Patent: October 31, 2000Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Darshan B. Makhey, Baoping Zhao, Leroy Fong Liu
-
Patent number: 6130227Abstract: 20S-Camptothecin derivatives in which the 7-position bears as a substituent --CN, --CH(CN)R.sub.4, --CH.dbd.C(CN)R.sub.4, --C(.dbd.NOH)NH.sub.2, --C(.dbd.NH)NH.sub.2, --CH.dbd.C(NO.sub.2)R.sub.4, --CH(CN)R.sub.5, --CH(CH.sub.2 NO.sub.2)R.sub.5, tetrazol-5-yl, 4,5-dihydrooxazol-2-yl, or 1,2,4-oxadiazolin-3-yl-5-one. These compounds are active as topoisomerase I inhibitors, and can be used as antitumor drugs.Type: GrantFiled: August 20, 1998Date of Patent: October 10, 2000Assignee: Istituto Nazional per Lo Studio e la Cura Dei TumoriInventors: Lucio Merlini, Sergio Penco, Franco Zunino
-
Patent number: 6130101Abstract: The present invention describes xanthene dyes, including rhodamines, rhodols and fluoresceins that are substituted one or more times by a sulfonic acid or a salt of a sulfonic acid. The dyes of the invention, including chemically reactive dyes and dye-conjugates are useful as fluorescent probes, particularly in biological samples.Type: GrantFiled: September 23, 1997Date of Patent: October 10, 2000Assignee: Molecular Probes, Inc.Inventors: Fei Mao, Wai-Yee Leung, Richard P. Haugland
-
Patent number: 6111107Abstract: The present invention is directed to methods of forming esters of tertiary alcohols. The methods include reacting a compound containing a tertiary alcohol with an acyl heteroaromatic ion-based compound of the formula: ##STR1## wherein R.sub.1 is an aromatic or aliphatic acid residue;Y is O or S;Z is R.sub.2 N;X is selected from the group consisting of ##STR2## wherein R.sub.2 and R.sub.3 are independently selected from the group consisting ofH, C.sub.1-6 alkyls, C.sub.1-6 substituted alkyls, C.sub.1-6 heteroalkyls, C.sub.3-8, branched alkyls, C.sub.3-8 cycloalkyls, C.sub.1-6 substituted heteroalkyls, aryls, substituted aryls, except that R.sub.2 is not H when X is ##STR3## C.sub.1-6 alkyl aralkyls, C.sub.1-6 heteroalkyl aralkyls, C.sub.3-8, branched alkyl aralkyls and C.sub.3-8 cycloalkyl aralkyls; and R.sub.2 ' is the same as R.sub.2 except that R.sub.2 ' is not H;in the presence of a lanthanide.sup.III metal-based catalyst and a base.Type: GrantFiled: November 20, 1997Date of Patent: August 29, 2000Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Annapurna Pendri, Hong Zhao
-
Patent number: 6111108Abstract: An extraction technique for the isolation of Camptothecin from plant matter of the Camptotheca Acuminata. The plant matter is loaded into a high-pressure vessel of a supercritical fluid extraction system and is pressurized with supercritical carbon dioxide to extract plant waxes or other waste. A modifier, preferably methanol, is then added resulting in the extraction of the Camptothecin into the solvent.Type: GrantFiled: June 30, 1998Date of Patent: August 29, 2000Assignee: Midwest Research InstituteInventors: Viorica Lopez-Avila, Janet V. Benedicto
-
Patent number: 6107304Abstract: Invented are substituted thieno (2,3-b)pyrazolo(3,4-d)pyridin-3-ones, pharmaceutical compositions containing these compounds, and methods of using these compounds to enhance erythropoiesis. Also invented are intermediates and processess used in preparing these compounds.Type: GrantFiled: June 7, 1999Date of Patent: August 22, 2000Assignee: SmithKline Beecham CorporationInventor: Juan Ignacio Luengo
-
Patent number: 6107486Abstract: Methods for purifying 20(S)-camptothecin are described. The 20(S)-camptothecin in purified form is useful in the treatment of cancer.Type: GrantFiled: August 8, 1997Date of Patent: August 22, 2000Assignee: The Stehlin Foundation for Cancer ResearchInventor: Hellmuth R. Hinz
-
Patent number: 6093721Abstract: A water soluble camptothecin derivative which is 20(S)-7-ethyl-9(N-methyl-N-phenyl)amidino-camptothecin and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and a process for their preparation are described. The compound of the invention and its pharmaceutically acceptable salts are useful antitumor agents and are further charactcrised by having a remarkable therapeutic index.Type: GrantFiled: May 13, 1999Date of Patent: July 25, 2000Assignee: Pharmacia & Upjohn S.p.A.Inventors: Angelo Bedeschi, Walter Cabri, Ilaria Candiani, Laura Capolongo
-
Patent number: 6057303Abstract: Derivatives of Camptothecin are disclosed, particularly derivatives having multiple substitutions at the `A`, `B` and `E` rings thereof. The novel compounds are useful in treating a wide variety of susceptible tumors and are potent inhibitors of Topoisomerase I.Type: GrantFiled: October 20, 1998Date of Patent: May 2, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Kochat Haridas, Frederick H. Hausheer
-
Patent number: 6043367Abstract: The present invention features proactive antitumor compounds of the following formula: ##STR1## wherein R.sup.1 is COOZ; Z being H, alkali metal, alkaline earth metal, an ammonium group which is optionally substituted with one or more alkyl groups, or a carboxyl protecting group; each of R.sup.2, R.sup.3, and R.sup.4, independently, is OH or OR.sup.a ; R.sup.a being a hydroxyl protecting group; X is benzene or pyridine, optionally substituted with R.sup.b ; R.sup.b being H, C.sub.1-5 alkyl, C.sub.1-5 alkoxy, NO.sub.2, F, Cl, Br, SO.sub.3 H, and CN; R.sup.5 is H or OH; and each of n and m, independently, is 0 or 1; or a salt thereof.Type: GrantFiled: September 30, 1998Date of Patent: March 28, 2000Inventors: Steve Roffler, Ji-Wang Chern, Ye-Lin Leu
-
Patent number: 6028078Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: October 26, 1998Date of Patent: February 22, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Pavankumar N. V. Petluru, Dasharatha Reddy, Dhanabalan Murali, Kochat Haridas, Peddaiahgari Seetharamulu, Shijie Yao
-
Patent number: 6028197Abstract: The present invention provides a 5,6-dihydrodibenzo[a,g]quinolizinium derivative and the salts thereof of formula (I) which specifically inhibits the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, and the use of the compound of formula (I) for treating hypercholesterolaemia or hyperlipidaemia. ##STR1## wherein, R.sup.1 and R.sup.2 which may be the same or different from each other, represent a hydroxy group or an alkoxy group having 1 to 4 carbons or R.sup.1 and R.sup.2 together represent a methylenedioxy group;R.sup.3 represents a hydroxy group or an alkoxy group having 1 to 4 carbons;R.sup.Type: GrantFiled: January 22, 1999Date of Patent: February 22, 2000Assignee: Hanwha CorporationInventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
-
Patent number: 6015901Abstract: A process for preparing S type 2-substituted hydroxy-2-indolidinyl-butyric ester compound [II]: ##STR1## wherein R.sup.0 is residue of nitrogen-containing fused heterocyclic carboxylic acid having absolute configuration of "R"(in which the nitrogen atom is protected), R.sup.1 and R.sup.2 are lower alkyl group, and E is ester residue, which is useful as an intermediate for preparing camptothecin derivatives having antitumor activities, which comprises 2-ethylating 2-substituted hydroxy-2-indolidinylacetic ester compound [I]: ##STR2## wherein the symbols are as defined above.Type: GrantFiled: October 15, 1998Date of Patent: January 18, 2000Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Takayuki Kawaguchi, Sumihiro Nomura, Kenji Tsujihara
-
Patent number: 6011042Abstract: The present invention is directed to conjugates such as polymeric prodrugs of aromatic, hydroxyl-containing compounds and methods of making and using the same. These polymeric prodrugs are preferably esters of hydroxyl-containing aromatic compounds and are formed by reacting a desired aromatic, hydroxyl-containing compound with a substantially non-antigenic polymer so as to produce a transport form having an ester linkage between the aromatic compound and the polymer. Preferred aromatic hydroxyl-containing compositions include 10- and 11-hydroxycamptothecin derivatives. Methods of treatment are also disclosed.Type: GrantFiled: October 10, 1997Date of Patent: January 4, 2000Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Annapurna Pendri, Yun H. Choe
-
Patent number: 6008356Abstract: The novel compounds of the following chemical formulae (I) and (II) exhibit in vitro antifungal activity against fungi including cutaneous filamentous fungus, such as Epidermophyton, Microsporum, Trichophyton, Sporothrix schenckii, Aspergillus or Candida. The compounds of the present invention exhibit in vitro antifungal activity at the concentration of 1-100 .mu.g/ml. ##STR1## wherein R.sup.1, R.sup.2, and R.sup.4 may be the same or different, and represent C.sub.1 -C.sub.5 alkoxy, R.sup.3 represents hydrogen or C.sub.1 -C.sub.10 alkyl, A.sup.- represents inorganic acid ion, organic acid ion or halide, R.sup.5 represents hydrogen, pyridylmethyl, substituted pyridylmethyl or a group having the following chemical formula(XI) ##STR2## wherein Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4 and Z.sup.5 may be the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.5 alkyl, trifluoromethyl, phenyl, substituted phenyl, nitro, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylamino, acetylamino, C.sub.1 -C.sub.Type: GrantFiled: December 10, 1998Date of Patent: December 28, 1999Assignee: Hanwha CorporationInventors: Jung Ho Kim, Tae Neung Jhong, Young Ki Paik, Joon Seo Park, Eui Deok Kim, You Suk Lee, Seung Un Kim
-
Patent number: 5998426Abstract: The present invention relates to 9-amino-10-(1-naphthylsulfonyloxy)-20(S)-camptothecin, 9-amino-10-phenylsulfonyloxy-20(S)-camptothecin, 7-ethyl-9-amino-10-(p-toluensulfonyloxy)-20(S)-camptothecin, their pharmaceutically acceptable salts, a process for their preparation, pharmaceutically compositions comprising them and their use as antitumor agents.Type: GrantFiled: September 29, 1997Date of Patent: December 7, 1999Assignee: Pharmacia & Upjohn S.p.A.Inventors: Angelo Bedeschi, Walter Cabri, Ilaria Candiani, Franco Zarini, Sergio Penco
-
Patent number: 5981541Abstract: The present invention provides compounds of formula (I): ##STR1## wherein R.sub.1 -R.sub.7, W, X, Y, and Z have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are are useful as anticancer agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of formula I, processes for preparing compounds of formula I, and intermediates useful for preparing compounds of formula I.Type: GrantFiled: September 23, 1997Date of Patent: November 9, 1999Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Leroy Fong Liu, Darshan B. Makhey
-
Patent number: 5981542Abstract: A camptothecin analog characterized in that the hydroxy lactone of the camptothecin is a .beta.-hydroxy lactone or the corresponding .beta.-hydroxyacid, resulting from the opening of said lactone, or a derivative of said .beta.-hydroxyacid, or a Pharmaceutically acceptable salt thereof, is disclosed. In particular, compounds of formulae (I) and (II) are disclosed. Methods for preparing the compounds of formulae (I) and (II), pharmaceutical compositions containing said containing said compounds, and their use, particularly as topoisomerase inhibitors and antitumoral drugs, are also disclosed.Type: GrantFiled: December 2, 1997Date of Patent: November 9, 1999Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Dennis Bigg, Olivier Lavergne, Francesc Pla Rodas, Jacques Pommier, Gerard Ulibarri
-
Patent number: 5972955Abstract: Novel water soluble C-ring analogs of 20(S)-camptothecin having the formula 1. ##STR1## The compounds of the formula 1 are prepared from the compounds of the formula 12 having C-20(S) chiral carbon. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties.Type: GrantFiled: December 19, 1996Date of Patent: October 26, 1999Assignee: Dr. Reddy's Research FoundationInventors: Subrahmanyam Duvvuri, Venkateswarlu Akella, Sharma Manohara Vedula, Archana Prabhakar Kulakarni
-
Patent number: 5968943Abstract: Derivatives of camptothecin are disclosed and are represented by the general formula: ##STR1## wherein when R.sub.2 is H, R.sub.1 is a C.sub.2 -C.sub.4 alkyl group, a C.sub.6 -C.sub.15 alkl group, a C.sub.3 -C.sub.8 cycloalkyl group, a C.sub.2 -C.sub.15 alkenyl group or a C.sub.2 -C.sub.15 epoxy group; and when R.sub.2 is a nitro group, R.sub.1 is a C.sub.1 -C.sub.15 alkyl group, a C.sub.2 -C.sub.15 alkenyl group, a C.sub.3 -C.sub.8 cycloalkyl group, or an epoxy group. Processes for mailing these derivatives and for using them in cancer treatment are also disclosed.Type: GrantFiled: February 25, 1998Date of Patent: October 19, 1999Assignee: The Stehlin Foundation for Cancer ResearchInventors: Zhisong Cao, Beppino C. Giovanella
-
Patent number: 5965566Abstract: The present invention is directed compositions of the formula: ##STR1## wherein: D is a residue of biologically active moiety;X is an electron withdrawing group;Y and Y' are independently O or S;(n) is zero (0) or a positive integer, preferably from 1 to about 12;wherein: R.sub.1 and R.sub.2 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C.sub.1-6 alkyls;wherein: R.sub.3 is a substantially non-antigenic polymer, C.sub.1-12 straight or branched alkyl or substituted allyl, C.sub.5-8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or ##STR2## wherein: R.sub.4 and R.sub.5 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C.sub.1-6 alkyls or jointly form a cyclic C.sub.5 -C.sub.7 ring.Type: GrantFiled: August 20, 1997Date of Patent: October 12, 1999Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Annapurna Pendri, Hong Zhao
-
Patent number: 5959110Abstract: The present invention is directed to a novel dopamine receptor ligands of the formula: ##STR1## pharmaceutical formulations of such compounds, and a method using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system.Type: GrantFiled: October 18, 1996Date of Patent: September 28, 1999Assignees: Purdue Research Foundation, University of North CarolinaInventors: David E. Nichols, Richard Mailman, Debasis Ghosh
-
Patent number: 5942518Abstract: A compound represented by Chemical Formula (1), and salts thereof are provided. A process for production thereof is also provided. The fluoroethylcamptothecin derivative has high antineoplastic activity, being less toxic, and water-soluble, thus is a useful compound.Type: GrantFiled: November 18, 1997Date of Patent: August 24, 1999Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Yoshikazu Asahina, Yasuo Oomori
-
Patent number: 5932732Abstract: A process for preparing S type 2-substituted hydroxy-2-indolidinyl-butyric ester compound ?II!: ##STR1## wherein R.sup.o is residue of nitrogen-containing fused heterocyclic carboxylic acid having absolute configuration of "R"(in which the nitrogen atom is protected), R.sup.1 and R.sup.2 are lower alkyl group, and E is ester residue, which is useful as an intermediate for preparing camptothecin derivatives having antitumor activities, which comprises 2-ethylating 2-substituted hydroxy-2-indolidinylacetic ester compound ?I!: ##STR2## wherein the symbols are as defined above.Type: GrantFiled: October 28, 1997Date of Patent: August 3, 1999Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Takayuki Kawaguchi, Sumihiro Nomura, Kenji Tsujihara
-
Patent number: 5922877Abstract: A method is disclosed for the preparation of 9-nitrocamptothecin which involves reacting 20-camptothecin with at least one inorganic nitrate salt and at least one acid effective in catalyzing the formation of a nitronium ion, where the reaction occurs at a temperature and for a time sufficient to form the 9-nitrocamptothecin. Also, methods of further purifying the 9-nitrocamptothecin by column chromatography or by reprecipatation is also disclosed.Type: GrantFiled: August 5, 1997Date of Patent: July 13, 1999Assignee: The Stehlin Foundation for Cancer ResearchInventor: Zhisong Cao
-
Patent number: 5916897Abstract: The present invention relates to compounds of the following formulas: ##STR1## which are endowed with antitumor activity. The invention also relates to methods of treating tumors using these compounds.Type: GrantFiled: December 31, 1996Date of Patent: June 29, 1999Assignee: Pharmacia & Upjohn S.p.A.Inventors: Walter Cabri, Ilaria Candiani, Franco Zarini, Angelo Bedeschi, Sergio Penco
-
Patent number: 5910491Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.Type: GrantFiled: August 19, 1997Date of Patent: June 8, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Pavankumar N.V. Petluru, Dasharatha Reddy, Dhanabalan Murali, Kochat Haridas, Peddaiahgari Seetharamulu, Shijie Yao
-
Patent number: 5892043Abstract: A camptothecin derivative comprising a compound of the formula ?I!: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are (A) adjacent two groups combine to form alkylene, or both are H, and one of the remaining three groups is --X.sub.n --Alk.sub.m --R.sup.6, and the other two are H, alkyl or halogen, or (B) adjacent two groups combine to form alkylene, and one of the carbon atoms of said alkylene group is substituted by --X.sub.n --Alk.sub.m --R.sup.6, and the remaining three groups are H, alkyl or a halogen, and one or two --CH.sub.2 -- of the alkylene in (A) or (B) may optionally be replaced by --O--, --S-- or --NH--, X is --O-- or --NH--, Alk is alkylene, R.sup.6 is --NH.sub.2, ##STR2## or --OH, m and n are both 0 or 1, or m is 1 and n is 0, which camptothecin compound is bound to a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 27, 1996Date of Patent: April 6, 1999Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Kenji Tsujihara, Takayuki Kawaguchi, Satoshi Okuno, Toshiro Yano
-
Patent number: 5880131Abstract: High molecular weight, water-soluble prodrugs of the formula: ##STR1## wherein: D is a biologically active moiety;M is X or Q;X is an electron withdrawing group;Q is a moiety containing a free electron pair positioned five or six atoms from Y';Y and Y' are oxygen or sulfur;R is a polyalkylene oxide; andZ is OH, C.sub.1-4 all moieties or ##STR2## are disclosed. In preferred embodiments, the prodrugs contain a polyethylene glycol having a molecular weight of at least about 20,000.Type: GrantFiled: September 29, 1995Date of Patent: March 9, 1999Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Annapurna Pendri
-
Patent number: 5872115Abstract: This invention is concerned with 2-ureido-benzamide compounds of the formula (1) ##STR1## in which R.sup.1 is H, halogen atom, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)dialkylamino and R.sup.2 is H, halogen atom, hydroxy, nitro, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.3 -C.sub.6) cycloalkylmethoxy, (C.sub.1 -C.sub.4) alkylthio, (C.sub.1 -C.sub.4) alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl or ##STR2## wherein j is an integer of from 0 to 2 and R.sup.3 and R.sup.4 are each independently H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkanoyl, (C.sub.1 -C.sub.4)alkylsulfonyl or (C.sub.1 -C.sub.4)alkylcarbamoyl, NR.sup.3 R.sup.4 can to form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring;X is a (C.sub.3 -C.sub.15)alkyl, (C.sub.3 -C.sub.6) cycloalkyl, (C.sub.3 -C.sub.6) cycloalkylmethyl, .omega.-(C.sub.1 -C.sub.4) alkoxy-(C.sub.1 -C.sub.4) alkyl group or ##STR3## wherein k is an integer of from 1 to 4 and R.sup.5 and R.sup.Type: GrantFiled: December 30, 1996Date of Patent: February 16, 1999Assignees: Grelan Pharmaceutical Co. Ltd., Laboratoires Fournier S.C.A.Inventors: Jean Binet, Christian Guffroy, Hirotaka Kasai, Nagatoshi Wagatsuma
-
Patent number: 5856487Abstract: A process for isolating berberine from plants is described. An oral formulation of berberine is described.Type: GrantFiled: July 2, 1997Date of Patent: January 5, 1999Assignee: National Institute of ImmunologyInventors: Shakti N. Upadhyay, Raman Prasad Yadav
-
Patent number: 5856333Abstract: The present invention relates to substituted camptothecin derivatives of formula (I) wherein the symbol - - - - represents a single or double bond; R.sub.1, R.sub.2 and R.sub.3 are as defined under (a) or (b) below: (a) R.sub.1 and R.sub.2 are, each independently, hydrogen; C.sub.1 -C.sub.4 alkyl; C.sub.3 -C.sub.7 cycloalkyl; phenyl C.sub.1 -C.sub.6 alkyl; an optionally substituted phenyl ring; --NR.sub.5 R.sub.6 wherein one of R.sub.5 and R.sub.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or benzyl and the other is hydrogen, C.sub.1 -C.sub.6 alkanoyl, an optionally substituted C.sub.1 -C.sub.6 alkoxycarbonyl, an optionally substituted benzoyl, phenyl C.sub.1 -C.sub.6 alkanoyl, an optionally substituted C.sub.1 -C.sub.6 alkoxycarbonyl, an optionally substituted phenoxycarbonyl or phenyl C.sub.1 -C.sub.6 alkoxycarbonyl, or R.sub.5 and R.sub.6, combined together with the nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring residue; COOR.sub.8 wherein R.Type: GrantFiled: January 27, 1997Date of Patent: January 5, 1999Assignee: Pharmacia & Upjohn S.p.A.Inventors: Walter Cabri, Ilaria Candiani, Angelo Bedeschi, Franco Zarini, Sergio Penco